A multinational, multicenter, randomized, double-blind, double-dummy, stratified, active controlled parallel group study comparing the efficacy and safety of intravenous zoledronic acid, 5 mg once yearly, and oral risedronate, 5 mg daily, in the prevention and treatment of corticosteroid induced osteoporosis
Latest Information Update: 24 May 2017
At a glance
- Drugs Zoledronic acid (Primary) ; Corticosteroids; Risedronic acid
- Indications Osteoporosis
- Focus Pharmacodynamics
- Sponsors Novartis; Novartis Pharmaceuticals
- 07 Feb 2015 Planned number of patients changed from 802 to 900 as per European Clinical Trial Register record.
- 03 May 2012 New trial record